Senzime AB (publ) announced additional new contracts with multiple top 10-rated US hospital systems. New customers include one of the leading pediatric hospitals in the US, as well as supply of TetraGraph systems to robotic surgery rooms of the highest ranked hospital system in the US. The new contracts address a market opportunity exceeding 20,000 patients per year. Every year, approximately 100 million patients receive neuromuscular blocking drugs as part of anesthesia to facilitate endotracheal intubation and optimize surgical conditions.

These drugs paralyze muscles required for breathing, hence accurate monitoring during surgery to secure each patient?s individual dose is paramount for patient safely. In robotic surgery, a deep neuromuscular blockade is preferred to create optimal surgical conditions, increasing the importance of accurate, real-time patient monitoring. Senzime?s TetraGraph is a quantitative neuromuscular monitoring system that is used by anesthesiologists at hundreds of leading hospitals across the globe.

Its proprietary technology helps anesthesiologists to accurately select the right dose of neuromuscular blocking drugs and their antagonists, as well as indicate when it is safe to allow patients to breathe on their own again after surgery.